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Introduction
Since 1980 the global prevalence of dia-
betes mellitus (DM) has nearly doubled
up to 422 million people worldwide in
2014 and is estimated to redouble in the
next 20 years [44]. In high-income coun-
tries, DM prevalence was 3 times higher
among 65–69 year old patients compared
to low income countries and peaked in
the 75–79 years age group (22%) [6].
Late complications of DM, such as my-
ocardial infarction, stroke, renal failure,
peripheral arterial occlusive disease, dia-
betic retinopathy and polyneuropathies,
negatively impact the quality of life and
daily functioning of patients, and repre-
sent major costs within healthcare sys-
tems [45]. In addition, hypoglycemia
has been associated with higher mortal-
ity and increased risks for falls and fall-
related injuries [23].
Intheolderdiabeticpopulation, type2
diabetes mellitus (T2DM) has a preva-
lence of up to 90% [12]. Its antihyper-
glycemic pharmacotherapy is challeng-
ing [35], particularly among frail older
adults with impaired physical functions
[36]. Diabetes mellitus may increase the
risk for frailty [10] and they both share
several pathophysiological mechanisms,
e.g. chronic low-grade inflammation, in-
sulin resistance and sarcopenia [2, 29],
the latter being a major contributing fac-
tor to pathophysiology of frailty.
Several national and international
medical societies have published guide-
lines for both T2DM [1, 13, 14, 25, 37,
39] and frail older persons with T2DM
[22]. However, recommendations are
mainly based on indirect evidence from
trials not including frail participants or
excluding older adults at all [14, 21].
This research group on medication
and quality of life in frail older per-
sons (MedQoL-Group) conducted four
extended systematic reviews on drug
treatment in hypertension [28], depres-
sion, dementia and T2DM. We included
trials with older persons who can be
characterized as frail in terms of im-
paired physical functioning, even if the
investigators of the primary studies did
not explicitly consider the concept of
frailty when planning their studies. This
article reports a systematic review of ran-
domized (RCT) and non-randomized
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lection of non-RCTs [26]
(Formore information visit
www.prisma-statement.
org)
prospective clinical trials (non-RCT)
intended to determine the effectiveness
and safety of pharmacotherapy for frail
older persons with T2DM characterized
as functionally significantly or severely
impaired.
Material andmethods
Thissystematicreviewisreportedaccord-
ing to the PRISMA guidelines [20] and
hasbeen specified inaprotocol registered
on PROSPERO (CRD42018108997,
https://www.crd.york.ac.uk/prospero).
Search and study eligibility
The databases MEDLINE (via Ovid),
Embase (via Ovid) and Cochrane Cen-
tral Register of Trials (CENTRAL) were
searched for randomized and non-
randomized prospective clinical trials
comparing antihyperglycemic pharma-
cotherapy versus placebo or other anti-
hyperglycemic medication or comparing
different HbA1c targets in older persons
with DM (see table S1 and table S2 for
Medline search strategies). In addition,
reference lists of included studies were
screened. Detailed search methods are
described in S3. Titles/abstracts and
full texts were assessed for eligibility by
two reviewers (CB, GT), independently.
Conflicts were solved by discussion or
a third reviewer (SVR).
RCTs and non-RCTs with control
group design reporting on persons
aged 65 years or older (or mean age
≥70 years) with T2DM and significant
orsevere impairmentofphysical function
were included. We assessed functional
impairment according to a compilation
ofpredefined thresholds in51 established
indices and scores [4]. For preparation of
this compilation, we limited our scope of
interest to assessments of frailty and, as
proxy indicators, instruments evaluating
activities of daily living (ADL) or phys-
ical functioning or impairment. With
regard to the latter we excluded assess-
ments of cognitive functioning. For each
identified instrument, we defined cut-off
scores for the categories (1) functionally
independent, (2) functionally slightly
impaired, (3) functionally significantly
impaired or partially dependent and
(4) functionally severely impaired or
disabled or dependent. In our review,
we only considered at least significantly
impaired populations.
Data extraction and risk of bias
assessment
One author extracted data from each
study and another checked data for accu-
racy and completeness. The two review-
ers worked independently on risk of bias
assessment. Conflicts were again solved
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Evidence gap on antihyperglycemic pharmacotherapy in frail older adults. A systematic review
Abstract
Background. Although antihyperglycemic
pharmacotherapy in frail older adults with
type 2 diabetesmellitus (T2DM) is challenging,
recommendations from international guide-
lines are mainly based on indirect evidence
from trials not including frail participants.
Objective. This systematic review inves-
tigated the effectiveness and safety of
pharmacotherapy in frail older adults with
T2DM.
Material and methods. Randomized (RCT)
and non-randomized prospective clinical trials
(non-RCT) were searched in three electronic
databases (Medline, Embase, Central) up
to October 2018. Trials in older adults with
T2DM who were assessed as significantly or
severely impaired by defined cut-off scores of
assessment instruments on frailty, activities of
daily living or physical functional impairment
were included.
Results. Two reviewers independently
screened 17,391 references for inclusion
and assessed risk of bias with ROBINS-I.
Five non-RCTs and no RCT were identified.
Treatment of T2DMwithout insulin compared
to insulin could be associatedwith increased
improvement in cardiac functions in patients
with cardiac resynchronization therapy and
with decreased falls in frail older women.
While better glycemic control with low
variability and low HbA1c (hemoglobin
A1c) values (<7%) was associated with
better maintenance of physical function in
community-dwelling older persons, higher
HbA1c values (8–8.9%) were associatedwith
a reduction in the composite outcome of
death or functional decline in community-
dwelling diabetic older adults with need for
skilled assistance. Due to serious risk of bias in
all studies, results should be considered with
caution.
Conclusion.Well-designed, large-scale RCTs
including this important group of patients are
required to assess the effectiveness and safety
of pharmacotherapy and HbA1c targets.
Keywords
Aged · Frailty · Diabetes mellitus · Drug
therapy · Systematic review
Evidenzmangel für die antihyperglykämische Pharmakotherapie gebrechlicher älterer Patienten. Ein
systematisches Review
Zusammenfassung
Hintergrund. Auch wenn die antihyper-
glykämische Pharmakotherapie von älteren,
gebrechlichen Patientenmit Typ-2-Diabetes
anspruchsvoll ist, basieren die Empfehlungen
internationaler Leitlinien hauptsächlich
auf indirekter Evidenz aus Studien, die
gebrechliche Patienten nicht einschließen.
Ziel der Arbeit. Dieser systematische
Review untersuchte die Wirksamkeit und
Sicherheit medikamentöser Therapien bei
gebrechlichen, älteren Patientenmit Typ-2-
Diabetes.
Material und Methoden. Bis Oktober 2018
wurden systematische Literatursuchen in
drei Datenbanken (Medline, Embase, Central)
nach randomisierten (RCTs) und prospektiven
nichtrandomisierten kontrollierten Studien
(Non-RCTs) durchgeführt. Studien bei älteren
Erwachsenenmit Typ-2-Diabetes, die durch
vorab definierte Schwellenwerte hinsichtlich
Gebrechlichkeit, Aktivitäten des täglichen
Lebens oder anderer Instrumente zur
Messung der körperlichen Gebrechlichkeit als
signifikant oder schwerwiegend funktionell
eingeschränkt beurteilt worden waren,
wurden eingeschlossen.
Ergebnisse. Zwei Review-Autoren un-
tersuchten unabhängig voneinander die
Einschlussfähigkeit von 17.391 Datenbank-
einträgen. Es wurden fünf Non-RCTs und
keine RCT identifiziert. Die Therapie von
Typ-2-Diabetes ohne Insulin könnte im
Vergleich zu einer Therapie mit Insulin mit
stärkeren Verbesserungen der Herzfunktion
bei Patientenmit kardialer Resynchronisation
und mit weniger Stürzen bei gebrechlichen
älteren Frauen assoziiert sein. In einer Studie
war eine bessere glykämische Kontrolle,
definiert durch weniger schwankende und
niedrigere HbA1c-Werte (<7%) mit einer
besseren Erhaltung der körperlichen Funktion
bei zu Hause lebenden gebrechlichen Älteren
mit Typ-2-Diabetes assoziiert. In einer anderen
Studie waren höhere HbA1c-Werte (8–8,9%)
mit einer Reduktion des zusammengesetzten
Endpunkts aus Mortalität oder funktioneller
Beeinträchtigung bei älteren, zu Hause
lebenden pflegebedürftigen Erwachsenen
mit Typ-2-Diabetes assoziiert. Aufgrund eines
schwerwiegenden Risikos für Bias in allen
Studien sollten die Ergebnisse mit Vorsicht
betrachtet werden.
Diskussion. Gut konzipierte, große randomi-
sierte kontrollierte Studien, die gebrechliche,
ältere Patienten explizit adressieren sind
notwendig, um die Wirksamkeit und
Sicherheit der medikamentösen Therapie und
der HbA1c-Ziele einzuschätzen.
Schlüsselwörter
Ältere Menschen · Ältere gebrechliche Men-
schen · Diabetes mellitus · Medikamentöse
Therapie · Systematisches Review
Zeitschrift für Gerontologie und Geriatrie
Reviews
Ta
bl
e
1
Ch
ar
ac
te
ris
tic
so
fi
nc
lu
de
d
st
ud
ie
s
St
ud
y
Se
tt
in
g
A
ge
ye
ar
s,
m
ea
n
(S
D
)
Fe
m
al
e
pe
rc
en
t
Fu
nc
ti
on
al
st
at
us
at
ba
se
lin
e
m
ea
n
(S
D
)
Co
m
pa
ri
so
n
O
ut
co
m
es
re
-
po
rt
ed
Ri
sk
of
Bi
as
Sc
hw
ar
tz
20
02
[3
3]
n
=
62
9
Co
m
m
un
ity
-d
w
el
lin
g
73
.8
(5
.0
)a
10
0
A
ny
di
ffi
cu
lty
in
IA
D
L:
59
%
a
G
rip
st
re
ng
th
:1
7.
9
kg
(4
.7
)a
Q
ua
dr
ic
ep
ss
tr
en
gt
h:
55
.4
kg
(2
7.
5)
a
5-
ch
ai
rt
es
t:
13
.8
s(
5.
2)
a
Po
or
ta
nd
em
st
an
d:
60
%
a
2-
m
ta
nd
em
w
al
k:
19
.1
s(
8.
8)
a
W
al
ki
ng
sp
ee
d:
0.
8
m
/s
(0
.2
)a
In
su
lin
vs
.n
o
in
su
lin
Fa
lls
Se
rio
us
Ph
am
20
03
[3
0]
n
=
73
N
ur
si
ng
an
d
re
si
de
nt
ia
l
ho
m
es
76
.0
(7
.9
)
63
a
Ka
tz
A
D
L:
70
%
de
pe
nd
en
t
In
su
lin
vs
.o
ra
ld
ru
gs
vs
.n
o
ph
ar
m
a-
co
lo
gi
ca
la
nt
id
ia
be
tic
tr
ea
tm
en
t
H
bA
1c
(%
):
<
6.
5%
vs
.6
.5
–8
%
vs
.>
8%
H
yp
og
ly
ce
m
ia
D
ep
re
ss
io
n
A
D
L
M
or
ta
lit
y
Se
rio
us
W
an
g
20
11
[4
3]
n
=
11
9
Co
m
m
un
ity
-d
w
el
lin
g
76
.3
(3
.4
)
55
SP
PB
:7
.6
(3
.4
)
H
bA
1c
:
po
or
er
vs
.b
et
te
rc
on
tr
ol
cl
as
s
Lo
w
er
ex
tr
em
ity
fu
nc
tio
n
Se
rio
us
Ya
u
20
12
[4
6]
n
=
36
7
Co
m
m
un
ity
-d
w
el
lin
g
w
ith
ne
ed
fo
rs
ki
lle
d
he
lp
80
(9
)
67
A
D
L-
sc
or
e
≤
8:
66
%
H
bA
1c
(%
):
<
7.
0%
vs
.7
.0
–7
.9
%
vs
.8
.0
–8
.9
%
vs
.
≥
9.
0%
Fu
nc
tio
na
ld
ec
lin
e/
de
at
h
Se
rio
us
Sa
rd
u
20
14
[3
2]
n
=
32
H
os
pi
ta
lp
at
ie
nt
sw
ith
ca
rd
ia
c
re
sy
nc
hr
on
iz
at
io
n
th
er
ap
y
81
.7
(6
.3
)
41
6-
m
in
w
al
k:
24
9
m
(5
0.
7)
In
su
lin
vs
.n
o
in
su
lin
6-
m
in
w
al
k
H
bA
1c
N
YH
A
cl
as
s
Se
rio
us
AD
L-
sc
or
e
co
ns
ist
so
ffi
ve
ac
tiv
iti
es
of
da
ily
liv
in
g
(b
at
hi
ng
,d
re
ss
in
g,
to
ile
tin
g,
tra
ns
fe
rri
ng
an
d
ea
tin
g)
,r
an
ge
s
fro
m
10
(in
de
pe
nd
en
t)
to
0
(c
om
pl
et
el
y
de
pe
nd
en
t),
H
bA
1c
he
m
og
lo
bi
n
A1
c,
IA
D
L
In
st
ru
m
en
ta
l
ac
tiv
iti
es
of
da
ily
liv
in
g,
Ka
tz
AD
L
co
ns
ist
so
fs
ix
ac
tiv
iti
es
of
da
ily
liv
in
g
(b
at
hi
ng
,d
re
ss
in
g,
to
ile
tin
g,
tra
ns
fe
r,
co
nt
in
en
ce
,e
at
in
g)
ra
ng
es
fro
m
0
(in
de
pe
nd
en
t)
to
12
(m
ax
im
al
le
ve
lo
fd
ep
en
de
nc
y)
,k
g
ki
lo
gr
am
,
m
m
et
er
,m
in
m
in
ut
es
,N
YH
A
Ne
w
Yo
rk
He
ar
tA
ss
oc
ia
tio
n,
ss
ec
on
ds
,S
PP
B
sh
or
tp
hy
sic
al
pe
rfo
rm
an
ce
ba
tte
ry
a C
al
cu
la
te
d
by
re
vi
ew
au
th
or
s
by discussion or consulting the third re-
viewer. Data extraction was carried out
in piloted data forms. The reviewers used
the risk of bias in nonrandomized stud-
ies of interventions (ROBINS-I) tool to
assess the riskofbiasof includedprospec-
tive cohort studies [40].
Results
We included five non-RCTs and no RCT
involving 1220 older persons with DM.
The flow of non-RCT and RCT inclusion
is presented in the PRISMA flowcharts
(. Fig. 1 and S1 Fig).
Characteristics of included studies
are mentioned in . Table 1. Mean ages
ranged from 73.8 to 81.7 years, follow-
up periods from 1 to 7 years. Studies
were performed from 1986 to 2012.
Three trials were supported by public
grant [33, 43, 46]. One study reported
to have no conflict of interest [32]. One
study did not report on conflict of in-
terests [30]. All studies were assessed
as serious risk of bias, mainly due to
important confounders not considered
in the analyses.
Insulin versus oral anti-
hyperglycemics versus no
pharmacological antidiabetic
treatment
Pham et al. compared 73 diabetic nurs-
ing home residents older than 60 years
regarding patterns of effective manage-
ment, DMcontrol and functional depen-
dency [30]. This observational study was
conducted in two nursing and two res-
idential homes in France. Items of DM
control and follow-up were prospectively
recorded. Functional dependency was
assessedusing the Katz index of activities
of daily living [17]. Katz scores were not
reported on detail at baseline, but only
a minor subsample (n= 17) were classi-
fiedas functionally independent. Change
in DMmanagement from baseline to the
18 months follow-up occurred in partic-
ipants receiving insulin from 26 to 27,
oral antihyperglycemics from 29 to 24,
and no treatment or diet alone from 18
to 22. Hypoglycemia occurred in 24 pa-
tients: 18 of 27 (67%) on insulin and 6
of 24 (25%) on oral antihyperglycemics.
Zeitschrift für Gerontologie und Geriatrie
At the end of the study 41 subjects had
depression: 15 of 27 (56%) on insulin, 14
of 24 (58%) on oral antihyperglycemics
and 12 of 22 (55%) without treatment
or diet alone. Associations between DM
management and functional dependency
were not reported for any subgroup.
Different HbA1c values
Pham et al. furthermore classified the
73 diabetic nursing home residents ac-
cording to the lowest HbA1c value:
19 participants had values lower than
6.5%; 20 between 6.5%and 8%; 15 higher
than 8% [30]. In 19 subjects, HbA1c
was never measured during the study
period. At the end of the 18-months
follow-up, 7 (36.8%), 5 (25%) and 4
(26.7%) participants had died, respec-
tively. In univariate ANOVA analysis
and χ2-test no relationships were found
between HbA1c range and changes in
the Katz index or mortality rate.
Wang and Hazuda evaluated the
impact of glycemic control on the main-
tenance of lower-extremity physical
function in 119 diabetic participants
aged 71 years or older [43]. Using a la-
tent growth mixture modelling, poor
glycemic control class was defined by
means of HbA1c> 7% and higher in-
trasubject variability, better control by
means of HbA1c< 7% and lower in-
tra-subject-variability. The comparison
of adjusted correlations in the change
from baseline scores of the Short Phys-
ical Performance Battery (SPPB) at 18
and 36 months revealed that improved
glycemic control was associated with
a better maintenance of physical func-
tion.
Yau et al. evaluated if HbA1c levels
predicted functional decline or death in
367 functional severely impaired com-
munity-dwelling older adults who were
unable to live independently [46]. Func-
tionalitywas assessed based onfiveADLs
(bathing, dressing, toileting, transferring
and eating) scoring between 0 (com-
pletely dependent) and 2 points (inde-
pendent) in each activity. Two-thirds of
participants had a baseline ADL score of
8 or less. Mortality, functional decline
plus the composite outcome of mortal-
ity and functional decline were reported
after 6, 12 and 24 months. After ac-
counting for confounders age, sex, race
or ethnicity, time enrolled in the study,
baseline activities of daily living, comor-
bidities (cancer, congestive heart failure,
chronic obstructive lung disease, renal
disease, dialysis) and medications (none,
oral medication, insulin), patients with
HbA1c levels of 8–8.9% had the low-
est and levels of <7% the highest risk
of death, functional decline and com-
posite outcome at 2 years. Only the re-
sult for the composite outcome in the
8.0–8.9%groupreachedstatisticalsignifi-
cance. Stratificationofanalysisaccording
to antidiabetic medications (oral antihy-
perglycemic medications only vs. any
insulin) showed similar results in both
groups.
Insulin versus no insulin
Schwartz et al. determined risk fac-
tors and the risk of falls in 530 insulin
treated and 99 non-insulin treated di-
abetic women aged 65 years or older
[33]. At baseline, there were significant
differences in characteristics of insulin
treated and non-insulin treated partici-
pants, e.g. 71% of insulin treated versus
57% of non-insulin treated women had
difficulties in instrumental activities of
daily living (walking two or three blocks,
climbing 10 steps, preparing own meals,
doing heavy housework and doing own
shopping). Time since diagnosis of di-
abetes also differed (17.4± 11.2 versus
11.3± 9.2 years). Functional measures at
baseline were grip strength, quadriceps
strength, walking speed, 5 chair test, tan-
dem stand and tandem walk. Within the
2-year follow-up, the incidence of falls
per person-year between the insulin and
non-insulin group significantly differed
in the total study sample (1.12 vs. 0.85)
and in age subgroups (70–74 years: 1.26
vs. 0.56; 80–84 years: 1.31 vs. 0.89).
Significantly more women taking insulin
fell more than once a year (35.4%) com-
pared to women receiving no insulin
(25.7%). There was no significant dif-
ference in persons who fell more than
twice a year (10.6% vs. 15.2%). Tandem
walk accounted for 23% of the associ-
ation between non-insulin-treated DM
and falling, which was the largest con-
tributing factor among all risk factors.
Together with poor performance on tan-
dem stand, both measures accounted for
30% of the association between non-in-
sulin-treated DM and falling and 26% of
the association between insulin-treated
DM and falling.
Sardu et al. determined the effects of
insulin (n= 12) versus no insulin ther-
apy (n= 18) in diabetic patients with
heart failure older than 75 years and
receiving a cardiac resynchronization
therapy implant [32]. The 6-min walk
improved from baseline to 12 months
in the insulin group from 243.2 (SD
52.2) to 259.6 (53.7)m and in the non-
insulin group from 254.7 (55.1) to 271.3
(56.4)m. Changes in 6-minwalk differed
not significantly between groups. Mean
New York Heart Association (NYHA)
functional class improved in the insulin
group from 3.38 (1.1) to 2.8 (0.7), but
significantly more in the non-insulin
group from 3.21 (1.0) to 2.05 (0.6).
HbA1c values remained stable in both
groups compared to baseline. Quality of
life was not reported.
Discussion
There is very low evidence that treat-
mentofT2DMwithout insulincompared
to insulin therapy might be associated
with improvement in cardiac functions,
in older diabetic patients with cardiac
resynchronization therapy [32] and with
decreased falls, in frail olderwomen [33];
however, subjects might have received
insulin due to severe diabetes of longer
duration, which may explain adverse
outcomes. While better glycemic con-
trol with low variability and low HbA1c
values (<7%) was associated with bet-
ter maintenance of physical function in
community-dwelling older persons [43],
higher HbA1c values (8.0–8.9%) were
associated with a reduction in the com-
posite outcome of death or functional
decline in community-dwelling diabetic
older adults with need for skilled assis-
tance (classified as nursing home eligible
[46]).
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Strengths and limitations
Strengths of this study were (1) the ex-
panded search (2) the use of up to date
and specific tools to assess the risk of bias,
and (3) the independent screening and
risk of bias assessment by two reviewers.
Although we specified assessments with
cut-off scores of frailty indicators a priori
and dependency in ADL has been vali-
datedas frailtyproxy [8], themain limita-
tion of our systematic review was the use
of proxy indicators and the retrospective
identification of the frail population in
eligible trials.
Based on the included studies, all with
highriskofbias, andthe indirectevidence
from excluded studies in the research
field (S4), we cautiously interpreted that
a critical assessment of the need for in-
sulin and its conservative use as well as
multimodal strategies to set and reach
individual moderate HbA1c targets [47]
might have beneficial effects in diabetic
frail older adults. Considering the find-
ings that both lowandhighHbA1c values
were associated with increased mortality
and cardiac events [7], we recommend
to follow current guidelines on T2DM in
older persons proposing a defined tar-
get range of HbA1c levels (7.5–8.5%) [1,
3]; however, hypothesizedpositive effects
of conservative insulin use and defined
HbA1c target ranges are to be evaluated
in future rigorous research.
Conclusion
Implications for practice
The very low evidence from the included
trials and the additional discussion of
indirect evidence from the excluded
studies suggest an essential evidence
gap so that firm recommendations for
antihyperglycemic pharmacotherapy in
frail older adults with physical functional
impairment cannot be drawn.
Implications for research
Well designed, large-scale RCTs, includ-
ing not the same team replications [15],
are required to establish the effective-
ness of implementing internationally es-
tablished guidelines, based on the most
recentpositionpapersmanagingfrailtyin
DM [38, 41]. To address the well-known
challenges in research with frail older
persons [34], we suggest a prospective
network meta-analysis [42] as method-
ological framework as well as coordi-
nated practice-based research networks
[11, 27] and patient representatives as
stakeholder partners to ensure rigorous
scientificmethods, sufficient recruitment
and a patient-centered and practice-ori-
ented study plan [9]. An evidence-based,
updated studyplan involving networking
and methodological expertise [5, 18] of
ongoingorrecentlypublishedRCTsinthe
field [19, 24, 31] should be established,
therefore avoidingwaste in research [16].
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